Skip to content

Michael Brenner, of Harvard Medical School, joins Scailyte as advisor

Professor Michael Brenner joins Scailyte

Michael Brenner joins Scailyte

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Michael Brenner MD, Elizabeth Fay Brigham Professor of Medicine at Harvard Medical School, joins Scailyte as an advisor to the Board of Directors.

Prof. Brenner is the director of Brigham and Women’s Hospital’s Human Immunology Center, which creates and performs single-cell transcriptional analysis and functional investigations in order to decipher human autoimmune illnesses, stratify patient groups, and find prospective therapeutic target cells and pathways. He is a member of the National Academy of Sciences in the United States and has received numerous awards.

Prof Brenner’s research focuses on T cell biology, antigen presentation, microbial pathogenesis, and autoimmunity. His research discovered the integrin molecule aEb7 (CD103) and its role in leukocyte homing, as well as a role for the CD1 antigen presentation system in the activation of T cells and NKT cells. His team has recently identified distinct fibroblast subpopulations that are pathologically expanded in disease, as well as a new T helper cell population, T peripheral helper (Tph) cells, that are implicated in antibody production in autoantibody-mediated disorders.

Michael Brenner, MD comments: “I am thrilled to support Scailyte in their pioneering efforts combining single-cell technologies and artificial intelligence for biomarker discovery. Single-cell technology is moving into the clinical space and Scailyte is there at the right moment to capture the potential and create a new generation of clinical applications that will make a difference for patients.”

About Scailyte

Scailyte is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary best-in-class data analysis platform ScaiVision associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision is the most powerful and cutting-edge approach to develop methods for precise diagnosis and prediction of therapy response. Scailyte leverages a global network of clinicians to identify disease indications with high unmet needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) and IVD assays. 

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

PAPER: Mapping single-cell data - Nature Biotech

Large single-cell atlases are now routinely generated to serve as references for the analysis of sma

Read more

Recent News

Scailyte Closes Financing Round and Onboards Top Biotech Leaders

Scailyte has successfully finished the first closing of their series A. Two new investors joined the

Read more

Recent News

Scailyte Quarterly Update December 2021

December 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

Why single-cell technologies are vital for Endometriosis research webinar

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

01 /04

PAPER: Mapping single-cell data - Nature Biotech

Large single-cell atlases are now routinely generated to serve as references for the analysis of sma

Read more

Scailyte Closes Financing Round and Onboards Top Biotech Leaders

Scailyte has successfully finished the first closing of their series A. Two new investors joined the

Read more

Recent News

02 /04

Scailyte Quarterly Update December 2021

December 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

03 /04

Why single-cell technologies are vital for Endometriosis research webinar

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

04 /04

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News